Patients want Blue Light Cystoscopy

A large survey posted by the Bladder Cancer Advocacy Network (BCAN) and published in UroToday revealed a growing preference for Cysview®.

A survey of 600 bladder cancer patients posted by the Bladder Cancer Advocacy Network (BCAN) in January revealed a growing preference for Blue Light Cystoscopy with Cysview. Of the respondents, 438 reported having received Cysview and said they were diagnosed at one facility, but then went to another that offers Blue Light Cystoscopy (BLC™) with Cysview.

Read more on UroToday